Company Profile
Edwards Lifesciences Stock Price, News & Catalysts
- Ticker:
- EW
- Exchange:
- NYSE
- Sector:
- Biopharma
- Location:
- United States
Stock performance
86.48 USD (-0.86%)
Close
Last updated: October 6, 2026
50.5B USD
Market cap
Why the stock is moving
As of Oct 6, 2026, EW closed down 0.86% at $86.48. No new same-company headline was identified in the current news window.
Company overview
Structural Heart Innovation Company
Edwards Lifesciences is a medical-technology company focused on structural heart disease and critical-care-related innovation. Its portfolio addresses aortic, mitral, and tricuspid valve disease through transcatheter and surgical technologies supported by clinical evidence, physician training, and specialized procedural infrastructure.
Transcatheter Aortic Valve Replacement
The TAVR business is centered on the SAPIEN platform, including the SAPIEN 3 Ultra RESILIA valve. Edwards develops transcatheter systems for patients across the aortic-stenosis disease pathway and uses long-term data from PARTNER, EARLY TAVR, and other studies to support earlier diagnosis, treatment, and broader adoption.
Mitral and Tricuspid Therapies
The Transcatheter Mitral and Tricuspid Therapies portfolio combines repair and replacement technologies. PASCAL provides transcatheter edge-to-edge repair, EVOQUE provides transcatheter tricuspid valve replacement, and SAPIEN M3 is a transcatheter mitral valve replacement system for patients who may not be well suited to repair.
Surgical Structural Heart Portfolio
Edwards supplies surgical valves and related systems using RESILIA tissue technology. Products include INSPIRIS, MITRIS, and KONECT, which are designed to provide durable valve performance across aortic and mitral procedures, together with ECLIPTIS for surgical left atrial appendage exclusion.
Evidence-Based Market Development
The company invests heavily in randomized trials, long-term follow-up, physician education, and center expansion. This model supports adoption of new structural-heart procedures by pairing product launches with evidence on survival, hospitalization, valve durability, and procedural outcomes.
Global Commercial Infrastructure
Edwards commercializes its technologies in the United States, Europe, Japan, and other international markets through specialized clinical support teams. New platforms are generally introduced through measured launches that open experienced centers gradually and emphasize procedural quality before broader expansion.
Future catalysts
- Presentation of PROGRESS trial results evaluating TAVR in moderate aortic stenosis at TCT in the fourth quarter of 2026.
- Presentation of CLASP IITR trial results at TCT in the fourth quarter of 2026.
- Expected U.S. approval and launch of the PASCAL system for tricuspid patients in the fourth quarter of 2026.
- Expected U.S. and European approvals of next-generation PASCAL with Capture Clarity technology in the fourth quarter of 2026.
- Measured U.S. rollout of the ECLIPTIS surgical left atrial appendage system later in 2026.
Recent news
- 01
- 02
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Edwards Lifesciences (EW)?
Edwards Lifesciences (EW) most recently closed at 86.48 USD, a -0.86% move versus the previous session.
What is the market cap of Edwards Lifesciences (EW)?
Edwards Lifesciences currently has a market capitalization of 50.5B USD on BioPharmSignal.
What does Edwards Lifesciences do?
Structural Heart Innovation Company Edwards Lifesciences is a medical-technology company focused on structural heart disease and critical-care-related innovation. Its portfolio addresses aortic, mitral, and tricuspid valve disease through transcatheter and surgical technologies supported by clinical evidence, physician training, and specialized procedural...
On which exchange is EW stock listed?
Edwards Lifesciences (EW) is associated with NYSE, United States, Biopharma.
What is Structural?
Structural Heart Innovation Company Edwards Lifesciences is a medical-technology company focused on structural heart disease and critical-care-related innovation.
Which conditions is Edwards Lifesciences targeting with Structural?
Structural Heart Innovation Company Edwards Lifesciences is a medical-technology company focused on structural heart disease and critical-care-related innovation. Its portfolio addresses aortic, mitral, and tricuspid valve disease through transcatheter and surgical technologies supported by clinical evidence, physician training, and specialized procedural...
How does Edwards Lifesciences describe recent progress with Structural?
Presentation of PROGRESS trial results evaluating TAVR in moderate aortic stenosis at TCT in the fourth quarter of 2026. Presentation of CLASP IITR trial results at TCT in the fourth quarter of 2026. Expected U.S. approval and launch of the PASCAL system for tricuspid patients in the fourth quarter of 2026. Expected U.S. and European approvals of...
What is Heart?
Structural Heart Innovation Company Edwards Lifesciences is a medical-technology company focused on structural heart disease and critical-care-related innovation.